Skip to main content
PolicySpeak
← All files
FZS

Farmac Zabban Spa

Company · Italy

not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.

2
positions filed
in the 665 files tracked
1
legislative file
of 665 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Track Farmac in PolicySpeak: request access →

Follow Farmac Zabban Spa

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at Farmac Zabban Spa? so we know who speaks for it.

Their record over time

Farmac Zabban Spa filed 2 positions between 6 Oct 2025 and 1 Jun 2026, across 1 of the 665 legislative files tracked here, attaching a full position paper 1 time.

2025 · 1 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 1 Jun 2026PDFsource

We strongly support the Targeted Revision of Regulation (EU) 2017/745 (MDR) and urge its swift adoption. The revision is a necessary and urgently needed corrective measure. With the long time of certification assessments, there would be a critical certification bottleneck from 2027, delays in enacting these reforms risk to face again the lack of MDR devices in the market with jeopardising patient access to safe and…

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025source

We are a company that produces and markets medical devices. In our opinion, the MDR imposes excessive bureaucratic burdens and a waste of resources. The assessment procedures are overregulated. We believe it does not add safety and quality compared to the MDD 93/42.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put Farmac Zabban Spa next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from Farmac Zabban Spa’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.